
Pfizer Inc.
PFEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 6, 2026 | FBN Securities | $34.00(+16%) | $29.31 | StreetInsider | |
| Nov 4, 2026 | Argus Research | David Toung | $40.00(+30%) | $30.79 | StreetInsider |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $28.00(+0%) | $28.00 | StreetInsider |
| Oct 6, 2026 | Scotiabank | $33.00(+21%) | $27.30 | TheFly | |
| Sep 10, 2026 | HSBC | $30.00(+8%) | $27.78 | TheFly | |
| Aug 7, 2026 | Guggenheim | $31.00(+18%) | $26.20 | TheFly | |
| Jul 6, 2026 | HSBC | $28.00(+15%) | $24.32 | TheFly | |
| May 27, 2026 | UBS | Michael Yee | $27.00(+2%) | $26.34 | StreetInsider |
| May 14, 2026 | Wolfe Research | Alexandria Hammond | $26.00(+0%) | $25.96 | TheFly |
| Mar 17, 2026 | Morgan Stanley | Terence Flynn | $27.00(-0%) | $27.05 | StreetInsider |
| Mar 9, 2026 | BMO Capital | Evan David Seigerman | $30.00(+13%) | $26.48 | StreetInsider |
| Feb 24, 2026 | RBC Capital | Trung Huynh | $25.00(-8%) | $27.14 | StreetInsider |
| Feb 19, 2026 | Barclays | Emily Field | $25.00(-7%) | $26.86 | TheFly |
| Feb 12, 2026 | Daiwa | Narumi Nakagiri | $27.00(-3%) | $27.73 | TheFly |
| Jan 27, 2026 | Cantor Fitzgerald | $27.00(+4%) | $25.88 | TheFly | |
| Jan 6, 2026 | UBS | $25.00(-2%) | $25.43 | TheFly | |
| Dec 17, 2025 | Wolfe Research | Alexandria Hammond | $24.00(-6%) | $25.53 | StreetInsider |
| Dec 12, 2025 | Morgan Stanley | $28.00(+8%) | $25.89 | TheFly | |
| Dec 10, 2025 | HSBC | Rajesh Kumar | $29.00(+14%) | $25.33 | TheFly |
| Nov 24, 2025 | Guggenheim | $35.00(+39%) | $25.17 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Freedom Broker | maintain | Buy | Nov 6, 2026 |
| Guggenheim | maintain | Buy | Nov 5, 2026 |
| UBS | maintain | Neutral | Nov 4, 2026 |
| Scotiabank | maintain | Sector Outperform | Nov 4, 2026 |
| Citigroup | maintain | Neutral | Nov 4, 2026 |
| RBC Capital | maintain | Sector Perform | Nov 4, 2026 |
| JP Morgan | maintain | Neutral | Oct 9, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Oct 8, 2026 |
| Scotiabank | maintain | Sector Outperform | Oct 6, 2026 |
| HSBC | maintain | Hold | Sep 10, 2026 |
| Guggenheim | maintain | Buy | Aug 7, 2026 |
| BMO Capital | maintain | Outperform | Jul 13, 2026 |
| Guggenheim | maintain | Buy | Jul 13, 2026 |
| B of A Securities | maintain | Neutral | Jul 10, 2026 |
| JP Morgan | maintain | Neutral | Jul 8, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Jul 6, 2026 |
| HSBC | downgrade | Buy →Hold | Jul 6, 2026 |
| RBC Capital | upgrade | Underperform →Sector Perform | Jun 10, 2026 |
| Citigroup | maintain | Neutral | Apr 29, 2026 |
| RBC Capital | maintain | Underperform | Apr 20, 2026 |
| UBS | maintain | Neutral | Apr 13, 2026 |
| Morgan Stanley | maintain | Equal Weight | Apr 10, 2026 |
| B of A Securities | maintain | Neutral | Apr 9, 2026 |
| Guggenheim | maintain | Buy | Mar 24, 2026 |
| HSBC | maintain | Buy | Mar 17, 2026 |
Earnings History
Next report: Feb 2, 2027 · EPS est. $0.69| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $0.87 | $0.73 | $16.58B | $15.85B |
| Aug 4, 2026 | $0.77 | $0.68 | $15.03B | $14.40B |
| May 5, 2026 | $0.75 | $0.72 | $14.45B | $13.84B |
| Feb 3, 2026 | $0.66 | $0.57 | $17.56B | $16.85B |
| Nov 4, 2025 | $0.87 | $0.63 | $16.65B | $16.50B |
| Aug 5, 2025 | $0.78 | $0.58 | $14.65B | $13.56B |
| Apr 29, 2025 | $0.92 | $0.67 | $13.71B | $13.92B |
| Feb 4, 2025 | $0.63 | $0.47 | $17.76B | $17.35B |
News
Eli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share. Pfizer had to drop its GLP-1 drug candidate, but quickly pivoted by acquiring a new GLP-1 drug still in development.
They are so much more than just dividend stocks.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Six S&P 500 'safer' high-yield dividend stocks—Regions Financial, Ford, AT&T, Pfizer, Verizon, VICI Properties—currently offer attractive buy signals based on free cash flow yields. Analyst projections for the top ten S&P 500 dividend dogs indicate potential net gains of 14.54% to 40.07% by November 2027, with an average estimated gain of 27.42%. Dividend dog strategy favors stocks where annual dividends from $1,000 invested exceed single-share prices and free cash flow yields surpass dividend y…
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.
After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's, while others spotted fresh opportunities worth a closer look.
Pfizer Inc. (NYSE: PFE - Get Free Report) shares reached a new 52-week high on Thursday after Guggenheim raised their price target on the stock from $31.00 to $33.00. Guggenheim currently has a buy rating on the stock. Pfizer traded as high as $31.44 and last traded at $31.2880, with a volume of 8,851,793 shares trading
Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.
When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim on that cash.
Associated Banc Corp bought a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 100,353 shares of the biopharmaceutical company's stock, valued at approximately $2,862,000. Several other hedge funds have also made changes to their positions in the business.
Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. PFE delivered a double-beat Q3, raised 2026 guidance, and posted strong non-COVID product growth, offsetting COVID-19 revenue declines. Major acquisitions combined with aggressive cost savings position PFE for strong post-LOE performance and diversification.
Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. PFE's non-COVID portfolio grew 7% operationally, with launched and acquired products up 32%, offsetting steep COVID-related declines. Management now guides 2026 revenue to $62–$64B and adjusted EPS to $2.95–$3.05, with cost savings and a 5.73% dividend yield well covered by FCF.
Pfizer raised 2026 revenue guidance to $62 billion to $64 billion. Launched and acquired products achieved 32% operational revenue growth in Q3.
On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Amazon.com, Inc. (NASDAQ:AMZN).
Pfizer NYSE: PFE reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.
Pfizer Inc. ( PFE ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO Cecile Guegan - Interim CFO & Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Alexandre de Germay - Executive VP & Chief International Commercial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Officer Conference Call Participants Christopher Schott -…
CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they file.